What Is SHBG (Sex Hormone-Binding Globulin, Male)? Normal vs Optimal Range Explained

The laboratory reference range for male SHBG spans 10–57 nmol/L—nearly a six-fold spread that obscures clinically critical information. SHBG acts as a testosterone sponge: it binds testosterone with high affinity, rendering it biologically inactive. Only the unbound "free" fraction (roughly 2–3% of total testosterone) can enter cells and activate androgen receptors. An SHBG of 55 nmol/L is technically normal but can bind so much testosterone that free T drops to hypogonadal levels despite a total testosterone in the healthy range. The CTD (Comparative Toxicogenomics Database) maps 1,156 gene–chemical interactions for SHBG and sex hormone transport proteins, confirming that hepatic SHBG production is regulated by insulin (suppresses), estrogen (raises), thyroid hormone (raises), and growth hormone (suppresses). The 20–40 nmol/L optimal range represents the equilibrium where sufficient testosterone remains free.

High SHBG is the most common reason men have low testosterone symptoms with "normal" total testosterone levels—and it's routinely missed because most physicians only order total testosterone. An SHBG of 50 nmol/L can reduce free testosterone by 40% compared to an SHBG of 25. PubMed indexes over 4,800 publications on SHBG in male hormonal health, consistently showing that SHBG rises with aging, hyperthyroidism, liver disease, and anticonvulsant medications. FAERS (FDA Adverse Event Reporting System) contains over 15,000 adverse event reports involving testosterone-related products, many involving men who were prescribed TRT based on total testosterone alone—when checking SHBG and free testosterone would have revealed the actual hormonal picture. For men over 40, SHBG rises approximately 1–2% per year, progressively binding more testosterone.

Low SHBG in men is equally problematic but in the opposite direction. An SHBG below 20 nmol/L is one of the earliest markers of insulin resistance and metabolic syndrome, often appearing before fasting glucose or HbA1c becomes abnormal. ChEMBL catalogs 387 bioactivity records for compounds affecting SHBG production, reflecting pharmaceutical interest in modulating this protein. When SHBG drops due to rising insulin, more testosterone circulates in free form—which sounds beneficial but actually accelerates aromatization (testosterone-to-estrogen conversion by aromatase enzyme in adipose tissue), leading to gynecomastia, increased body fat, and paradoxically worsened hormonal balance. Low SHBG with high fasting insulin demands metabolic intervention—not testosterone therapy.